Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FR8ET
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,786
Award facts
- Contract value 100% obligated
- $3,785.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,785.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injectors. The contract, issued on April 23, 2025, with an ultimate completion date of April 24, 2025, utilizes firm fixed-price pricing under a delivery order contract type with no set-aside designation. This award represents a discrete fulfillment request under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499,999,999 vehicle valid through November 2026 that enables the agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products supporting military health facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through consistent contract performance with the DLA. The company specializes in distributing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare systems across the nation. Nucala (mepolizumab), an injectable biologic used for severe eosinophilic asthma management, represents the type of specialty pharmaceutical product the company regularly procures for military medical facilities. This delivery order exemplifies the routine operational fulfillment activities executed under the broader SPE2DB IDC framework.
Quick answers
Who was awarded contract SPE2DB25FR8ET?
SPE2DB25FR8ET was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on April 23, 2025.
How much is contract SPE2DB25FR8ET worth?
The government has obligated $3,786 on SPE2DB25FR8ET.
Is contract SPE2DB25FR8ET an order under another contract?
Yes. SPE2DB25FR8ET is a delivery order under SPE2DB22D9225, an indefinite delivery contract.
Was contract SPE2DB25FR8ET competed?
The extent of competition for SPE2DB25FR8ET was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award